Jennison Associates LLC grew its position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 29.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 377,894 shares of the company's stock after buying an additional 86,399 shares during the period. Jennison Associates LLC owned 0.64% of Twist Bioscience worth $17,073,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in TWST. Signaturefd LLC lifted its stake in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience during the second quarter valued at about $43,000. Blue Trust Inc. raised its stake in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience in the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after purchasing an additional 381 shares during the period.
Twist Bioscience Price Performance
Shares of TWST traded up $0.57 during midday trading on Friday, reaching $42.23. The stock had a trading volume of 717,627 shares, compared to its average volume of 901,886. The company's fifty day simple moving average is $43.78 and its two-hundred day simple moving average is $46.10. The company has a market cap of $2.51 billion, a price-to-earnings ratio of -11.73 and a beta of 1.78. Twist Bioscience Co. has a 1-year low of $23.07 and a 1-year high of $60.90.
Insider Transactions at Twist Bioscience
In related news, CEO Emily M. Leproust sold 1,730 shares of Twist Bioscience stock in a transaction on Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $81,206.20. Following the sale, the chief executive officer now directly owns 495,523 shares in the company, valued at $23,259,849.62. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 659 shares of the company's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $27,388.04. Following the completion of the transaction, the insider now owns 94,481 shares of the company's stock, valued at $3,926,630.36. This represents a 0.69 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 98,118 shares of company stock valued at $4,391,151. Corporate insiders own 3.92% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have commented on TWST. JPMorgan Chase & Co. upped their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research note on Monday, August 5th. Evercore ISI raised their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday. Leerink Partners raised their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. Finally, Scotiabank increased their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience has an average rating of "Moderate Buy" and an average price target of $51.78.
View Our Latest Research Report on TWST
Twist Bioscience Profile
(
Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Further Reading
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
